Participated · Series C · Jun 2026

Float offers a unified platform for Canadian businesses that includes high-limit corporate cards in CAD and USD, automated expense management, next-day bill payments, high-yield business accounts, working capital credit, and cross-border payments built for Canada’s regulatory and bilingual requirements. The company serves more than 7,500 Canadian businesses and reports that since its Series B it has doubled its active customer base, grown revenue over 120%, and seen business account balances rise more than 4.5x. Volumes across five products are up over 100%, and nearly a third of customers now use more than one product. Float operates with a roughly 170-person team and says revenue per employee has increased about 50%. The company is advancing Float Intelligence, its proprietary AI layer, and is using recent funding to expand geographically and increase hiring.

Participated · Equity · Feb 2026

Neo Financial builds consumer financial products including a suite of credit cards, Everyday Accounts, Neo Savings, Neo Invest, and Neo Mortgage, and operates Neo for Partners which powers financial solutions for over 10,000 partners. The company serves more than one million customers and offers one of Canada’s lowest mortgage rates. Founded in 2019, Neo is headquartered in Calgary, Winnipeg, and Toronto and has raised more than $650 million in funding. It has been recognized as Canada's top-growing company by The Globe and Mail and placed #1 on the Deloitte Technology Fast 50 for three consecutive years. Neo recently completed a $150 million inaugural credit card securitization to access institutional capital and support growth of its credit card portfolio.

Led · Equity · Apr 2025

GoldState Music is a private investment firm that focuses on the music sector, investing in music rights, enterprises in need of growth and expansion capital, and emerging music technology. Founded in 2022, the firm operates offices in West Palm Beach, FL and Lake Nona, FL (Orlando). The team consists of experienced industry professionals deeply rooted in the music ecosystem. GoldState’s core product is a music rights investment platform that acquires and monetizes music assets on behalf of artists and investors. The company said it will use new capital to accelerate acquisitions, build a diversified portfolio across artists and genres, and meet growing artist demand for rights monetization. In recent activity it raised US$500 million in strategic capital, including a structured capital facility and separately raised leverage, to support its strategy and growth.

Led · Equity · Mar 2025

Shared Tower develops and owns carrier-neutral communications infrastructure under a shared infrastructure model aimed at enhancing connectivity for Canadians. The company operates under long-term contracts and is described as a preferred partner due to its flexible, solutions-based approach and reliable project delivery. Shared Tower was established in 2021 by CEO Dan Gibbons and is based in Oakville, Ontario. Northleaf Capital Partners has made an initial commitment of C$100 million to accelerate Shared Tower’s vision and help the company scale to better serve existing and new customers. The investment aligns with Shared Tower’s focus on contracted cashflow and network buildout under a shared infrastructure model. Northleaf was advised on the transaction by CIBC Capital Markets and Davies Ward Phillips & Vineberg.

Participated · Series C · Jun 2024

Bright Peak Therapeutics is a biotechnology company developing next-generation, multifunctional immunotherapies. Its lead program, BPT567, is the first PD1-IL18 immunoconjugate designed to simultaneously block the PD(L)-1 checkpoint pathway and deliver IL-18 signaling to effector T cells in the tumor microenvironment. In preclinical models, BPT567 induced profound synergistic anti-tumor activity with more limited activation of immune cells in the periphery. The company raised $90 million in a Series C financing led by Johnson & Johnson Innovation – JJDC to advance BPT567 into a Phase 1/2a clinical trial expected to begin in the second half of 2024 and to accelerate its pipeline of next-generation immunotherapies. Bright Peak leverages protein engineering and a proprietary chemical protein synthesis and conjugation platform to discover and develop first-in-class protein therapeutics. The company is based in Basel, Switzerland and San Diego, CA and is funded by a syndicate of leading healthcare investors. Bright Peak uses a proprietary Enhanced Design and Combine (EDC) chemistry platform to chemically synthesize therapeutic cytokines by ligating customized peptide segments, enabling tuning of cytokine biology through affinity modification and site-specific conjugation. The platform also permits conjugation of enhanced cytokines as payloads to antibodies, creating “Bright Peak Immunocytokines” for tissue- and cell-specific targeting with potential synergistic efficacy via avidity effects. The company is advancing a pipeline that includes programs across IL-2, IL-18 and IL-7. Management says the financing will allow expansion of the Immunocytokine platform and advancement of its development programs. Bright Peak is a privately held biotech with operations in San Diego, CA and Basel, Switzerland. Bright Peak Therapeutics builds a chemistry-driven platform, licensed from ETH Zürich, that chemically assembles proteins de novo and enables specific atom-level modifications and multi-site conjugations. The platform supports introduction of conjugation handles to create portfolios of conjugated or multi-targeted products and has been validated by a portfolio of designer cytokines. Internal programs include modified IL-2, IL-18 and IL-7 constructs, with an IL-2 development candidate in IND-enabling studies and ongoing scale-up and CMC campaigns. The company expects to enter the clinic within a year and plans to select a second development candidate later in the year. Bright Peak operates across Basel and San Diego, has recruited CEO Sef Kurstjens, and intends to expand its team from about 20 to more than 30 scientists. It will pursue pharma partners alongside financial investors to advance and commercialize its pipeline.